X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3122) 3122
Book Review (441) 441
Publication (164) 164
Newsletter (10) 10
Newspaper Article (10) 10
Magazine Article (7) 7
Conference Proceeding (6) 6
Transcript (2) 2
Book Chapter (1) 1
Dissertation (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2861) 2861
humans (2823) 2823
female (1946) 1946
male (1762) 1762
middle aged (1637) 1637
melphalan - administration & dosage (1328) 1328
adult (1325) 1325
aged (1293) 1293
oncology (1288) 1288
hematology (1197) 1197
melphalan (1175) 1175
melphalan - adverse effects (1016) 1016
antineoplastic combined chemotherapy protocols - therapeutic use (944) 944
chemotherapy (855) 855
multiple myeloma - drug therapy (808) 808
transplantation (785) 785
treatment outcome (733) 733
multiple myeloma (724) 724
antineoplastic combined chemotherapy protocols - adverse effects (696) 696
melphalan - therapeutic use (639) 639
stem-cell transplantation (522) 522
transplantation, autologous (498) 498
cancer (486) 486
combined modality therapy (474) 474
therapy (464) 464
bortezomib (429) 429
stem cells (419) 419
immunology (418) 418
multiple myeloma - therapy (398) 398
care and treatment (394) 394
survival (384) 384
abridged index medicus (378) 378
antineoplastic combined chemotherapy protocols - administration & dosage (374) 374
adolescent (373) 373
retrospective studies (371) 371
prognosis (347) 347
cyclophosphamide - administration & dosage (343) 343
disease-free survival (342) 342
aged, 80 and over (328) 328
hematopoietic stem cell transplantation (321) 321
survival rate (314) 314
survival analysis (311) 311
dexamethasone (309) 309
follow-up studies (306) 306
high-dose melphalan (296) 296
cyclophosphamide (290) 290
multiple myeloma - mortality (287) 287
stem cell transplantation (276) 276
thalidomide (274) 274
prednisone (257) 257
hematopoietic stem cell transplantation - adverse effects (254) 254
bone-marrow-transplantation (253) 253
child (253) 253
transplantation conditioning - methods (249) 249
dexamethasone - administration & dosage (242) 242
prednisone - administration & dosage (239) 239
antineoplastic agents, alkylating - administration & dosage (237) 237
hematopoietic stem cells (237) 237
antineoplastic agents - adverse effects (235) 235
antineoplastic agents - therapeutic use (230) 230
cyclophosphamide - adverse effects (230) 230
medicine & public health (230) 230
dose-response relationship, drug (229) 229
multiple-myeloma (227) 227
recurrence (220) 220
risk factors (219) 219
child, preschool (218) 218
time factors (216) 216
toxicity (216) 216
analysis (215) 215
hematopoietic stem cell transplantation - methods (215) 215
bone-marrow transplantation (214) 214
dosage and administration (213) 213
health aspects (211) 211
remission induction (211) 211
antineoplastic agents, alkylating - adverse effects (210) 210
etoposide - administration & dosage (208) 208
antineoplastic agents - administration & dosage (203) 203
thalidomide - administration & dosage (199) 199
trial (194) 194
drug administration schedule (193) 193
prospective studies (191) 191
carmustine - administration & dosage (189) 189
hematology, oncology and palliative medicine (186) 186
research (182) 182
drug therapy, combination (181) 181
multiple myeloma - pathology (178) 178
animals (176) 176
bone marrow transplantation (176) 176
boronic acids - administration & dosage (176) 176
pyrazines - administration & dosage (176) 176
doxorubicin - administration & dosage (175) 175
cytarabine - administration & dosage (174) 174
neoplasm staging (174) 174
vincristine - administration & dosage (172) 172
drug therapy (170) 170
surgery (170) 170
infant (167) 167
melanoma - drug therapy (166) 166
young adult (163) 163
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2954) 2954
German (42) 42
French (39) 39
Russian (37) 37
Japanese (29) 29
Spanish (18) 18
Italian (8) 8
Chinese (5) 5
Polish (4) 4
Czech (3) 3
Korean (3) 3
Norwegian (3) 3
Dutch (2) 2
Hebrew (2) 2
Croatian (1) 1
Danish (1) 1
Portuguese (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Oncology Pharmacy Practice, ISSN 1078-1552, 10/2019, Volume 25, Issue 7, pp. 1631 - 1637
Introduction For multiple myeloma patients who respond to primary therapy, autologous hematopoietic stem cell transplant (HSCT) is considered standard of care... 
autologous stem cell transplant | propylene glycol-free melphalan | melphalan | Multiple myeloma | hematopoietic stem cell transplant | Formulations | Autografts | Therapy | Propylene glycol | Mucositis | Toxicity | Stem cell transplantation | Hematopoietic stem cells | Hemopoiesis | Propylene | Side effects | Stem cells | Melphalan | Conditioning | Index Medicus
Journal Article
JOURNAL OF ORAL PATHOLOGY & MEDICINE, ISSN 0904-2512, 05/2018, Volume 47, Issue 5, pp. 477 - 483
Background: The cytotoxic effect of chemotherapeutic agents to the oral mucosa, as a side effect of cancer treatment, is a major problem. Cooling the oral... 
oral mucositis | MULTIPLE-MYELOMA | tissue-engineered oral mucosa | MANAGEMENT | invitro | MECHANISMS | cryotherapy | PATHOLOGY | chemotherapy | CANCER | 5-FLUOROURACIL | THERAPY | DENTISTRY, ORAL SURGERY & MEDICINE | STEM-CELL TRANSPLANTATION | MELPHALAN | SEVERITY
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 10, pp. 895 - 905
In patients 65 or younger with multiple myeloma, high-dose consolidation therapy was associated with longer survival and more myelotoxicity than... 
MEDICINE, GENERAL & INTERNAL | PREDNISONE | PLUS DEXAMETHASONE | INDUCTION THERAPY | LENALIDOMIDE | INITIAL TREATMENT | RANDOMIZED CONTROLLED-TRIAL | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Transplantation, Autologous | Consolidation Chemotherapy | Antineoplastic Agents, Alkylating - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Adult | Maintenance Chemotherapy | Neutropenia - chemically induced | Thalidomide - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Aged | Antineoplastic Agents, Alkylating - adverse effects | Stem Cell Transplantation - adverse effects | Complications and side effects | Care and treatment | Patient outcomes | Multiple myeloma | Stem cells | Transplantation | Research | Health aspects | Autografts | Chemotherapy | Cell survival | Transplants & implants | Melphalan | Stem cell transplantation | Death | Prednisone | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 5, pp. 592 - 598
Purpose To assess therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) risk in patients treated for Hodgkin lymphoma (HL) on successive... 
2ND CANCER-RISK | RANDOMIZED-TRIALS | ONCOLOGY | DNA TOPOISOMERASE-II | ALKYLATING-AGENTS | COMBINED-MODALITY TREATMENT | DISEASE | MYELOID-LEUKEMIA | MYELODYSPLASTIC SYNDROMES | CHEMOTHERAPY | ACUTE PROMYELOCYTIC LEUKEMIA | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hodgkin Disease - pathology | Humans | Leukemia, Myeloid, Acute - epidemiology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Mechlorethamine - adverse effects | Male | Risk | Leukemia, Myeloid, Acute - etiology | Incidence | Hodgkin Disease - radiotherapy | Melphalan - adverse effects | Chemotherapy, Adjuvant - adverse effects | Radiotherapy, Adjuvant - adverse effects | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Adult | Female | Retrospective Studies | Databases, Factual | Radiotherapy Dosage | Prednisone - adverse effects | Drug Administration Schedule | California - epidemiology | Clinical Trials as Topic | Bleomycin - adverse effects | Academic Medical Centers | Myelodysplastic Syndromes - epidemiology | Myelodysplastic Syndromes - etiology | Neoplasms, Second Primary - epidemiology | Neoplasms, Second Primary - etiology | Methotrexate - adverse effects | Procarbazine - adverse effects | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Index Medicus | Hema14 | Hema13 | Hema12 | ORIGINAL REPORTS
Journal Article
Blood, ISSN 0006-4971, 05/2012, Volume 119, Issue 20, pp. 4619 - 4624
Approximately 5-10% of diffuse large B-cell lymphomas (DLBCL) harbor a 8q24/MYC rearrangement (MYC+). We determined the prognostic significance of MYC... 
REARRANGEMENT | IMPACT | POOR-PROGNOSIS | T(14/18) | IN-SITU HYBRIDIZATION | CLASSIFICATION | HEMATOLOGY | EXPRESSION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Podophyllotoxin - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Cisplatin - administration & dosage | Young Adult | Lymphoma, Large B-Cell, Diffuse - therapy | Melphalan - adverse effects | Immunotherapy | Treatment Failure | Podophyllotoxin - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Carmustine - adverse effects | Genes, myc - physiology | Dexamethasone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Ifosfamide - adverse effects | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Cytarabine - administration & dosage | Lymphoma, Large B-Cell, Diffuse - mortality | Melphalan - administration & dosage | Ifosfamide - administration & dosage | Cisplatin - adverse effects | Aged | Hematopoietic Stem Cell Transplantation - methods | Antibodies, Monoclonal, Murine-Derived - adverse effects | Lymphoma, Large B-Cell, Diffuse - genetics | Carmustine - administration & dosage | Index Medicus | Abridged Index Medicus | Life Sciences | Biochemistry, Molecular Biology | Lymphoma, Large B-Cell, Diffuse | Podophyllotoxin | methods | Genes, myc | Cytarabine | genetics | administration & dosage | Melphalan | Antibodies, Monoclonal, Murine-Derived | Dexamethasone | drug therapy | Ifosfamide | Carmustine | therapy | Antineoplastic Combined Chemotherapy Protocols | Etoposide | physiology | Hematopoietic Stem Cell Transplantation | Cisplatin | adverse effects | mortality | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2014, Volume 32, Issue 7, pp. 634 - 640
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 8, pp. 986 - 993
Purpose In patients with myeloma, thalidomide significantly improves outcomes but increases the risk of thromboembolic events. In this randomized, open-label,... 
LOW-DOSE WARFARIN | DEXAMETHASONE | THERAPY | VENOUS THROMBOEMBOLISM | ONCOLOGY | DEEP-VEIN THROMBOSIS | PREDNISONE PLUS THALIDOMIDE | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Warfarin - adverse effects | Male | Antineoplastic Agents - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Multiple Myeloma - drug therapy | Thromboembolism - prevention & control | Time Factors | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Cardiovascular Diseases - mortality | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - etiology | Risk Assessment | Multiple Myeloma - complications | Risk Factors | Anticoagulants - therapeutic use | Treatment Outcome | Thromboembolism - etiology | Thromboembolism - mortality | Thalidomide - administration & dosage | Anticoagulants - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Hemorrhage - chemically induced | Index Medicus
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 01/2011, Volume 46, Issue 1, pp. 98 - 104
Dyskeratosis congenita (DC) is characterized by reticular skin pigmentation, oral leukoplakia and abnormal nails. Patients with DC have very short telomeres... 
hematopoietic cell transplantation | dyskeratosis congenita | reduced-intensity conditioning regimen | ALEMTUZUMAB | HOYERAAL-HREIDARSSON-SYNDROME | BONE-MARROW-TRANSPLANTATION | ANTITHYMOCYTE GLOBULIN | IMMUNOLOGY | FANCONI-ANEMIA | FLUDARABINE | FAILURE | TRANSPLANTATION | CORD BLOOD TRANSPLANTATION | ONCOLOGY | HEMATOLOGY | APLASTIC-ANEMIA | MELPHALAN | Antibodies, Neoplasm - therapeutic use | Cyclophosphamide - administration & dosage | Peripheral Blood Stem Cell Transplantation - adverse effects | Humans | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Whole-Body Irradiation - adverse effects | Young Adult | Antibodies, Monoclonal, Humanized | Cord Blood Stem Cell Transplantation - adverse effects | Antineoplastic Agents - adverse effects | Dyskeratosis Congenita - therapy | Hematopoietic Stem Cell Transplantation - adverse effects | Female | Transplantation Conditioning - adverse effects | Transplantation Conditioning - methods | Pulmonary Fibrosis - etiology | Vidarabine - adverse effects | Vidarabine - analogs & derivatives | Alemtuzumab | Antibodies, Neoplasm - administration & dosage | Vidarabine - therapeutic use | Combined Modality Therapy - adverse effects | Dyskeratosis Congenita - physiopathology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Pulmonary Fibrosis - prevention & control | Bone Marrow Transplantation - adverse effects | Vidarabine - administration & dosage | Antibodies, Neoplasm - adverse effects | Epithelial cells | Patient outcomes | Abnormalities | Physiological aspects | Development and progression | Transplantation | Hematopoietic stem cells | Risk factors | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 08/2010, Volume 116, Issue 5, pp. 679 - 686
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9758, pp. 2075 - 2085
Journal Article